$1.52 Billion is the total value of Casdin Capital, LLC's 37 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EQRX INC | $195,662,000 | +5.5% | 39,527,669 | 0.0% | 12.85% | -18.0% | ||
| BLFS | BIOLIFE SOLUTIONS INC | $172,133,000 | +64.7% | 7,566,292 | 0.0% | 11.31% | +28.0% | |
| IPSC | CENTURY THERAPEUTICS INC | $31,711,000 | +17.7% | 3,206,380 | 0.0% | 2.08% | -8.5% | |
| ABSCI CORPORATION | $24,159,000 | -5.7% | 7,718,593 | 0.0% | 1.59% | -26.8% | ||
| SEMA4 HOLDINGS CORP | $14,424,000 | -30.4% | 16,437,500 | 0.0% | 0.95% | -45.9% | ||
| TENAYA THERAPEUTICS INC | $10,402,000 | -48.5% | 3,586,818 | 0.0% | 0.68% | -60.0% | ||
| 2SEVENTY BIO INC | $8,945,000 | +10.2% | 614,754 | 0.0% | 0.59% | -14.3% | ||
| CLDX | CELLDEX THERAPEUTICS INC NEW | $4,638,000 | +4.3% | 165,000 | 0.0% | 0.30% | -18.9% | |
| GLUE | MONTE ROSA THERAPEUTICS INC | $4,174,000 | -15.5% | 510,882 | 0.0% | 0.27% | -34.4% | |
| KRON | KRONOS BIO INC | $415,000 | -8.0% | 123,839 | 0.0% | 0.03% | -28.9% | |
| LIANBIOsponsored ads | $411,000 | -7.8% | 206,415 | 0.0% | 0.03% | -28.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-22 |
| SC 13D/A | 2024-05-22 |
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-15 |
| 4 | 2024-05-02 |
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.